{"id":"NCT01241552","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10-10","primaryCompletion":"2014-12-09","completion":"2014-12-09","firstPosted":"2010-11-16","resultsPosted":"2016-12-15","lastUpdate":"2018-09-05"},"enrollment":1452,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Clostridium Difficile Infection"],"interventions":[{"type":"BIOLOGICAL","name":"MK-3415","otherNames":[]},{"type":"BIOLOGICAL","name":"MK-6072","otherNames":[]},{"type":"BIOLOGICAL","name":"MK-3415A","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"SOC","otherNames":[]}],"arms":[{"label":"MK-3415 + SOC","type":"EXPERIMENTAL"},{"label":"MK-6072 + SOC","type":"EXPERIMENTAL"},{"label":"MK-3415A + SOC","type":"EXPERIMENTAL"},{"label":"Placebo + SOC","type":"PLACEBO_COMPARATOR"}],"summary":"This study will investigate whether: 1) treatment with MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium difficile infection (CDI) recurrence as compared to treatment with MK-6072 or MK-3415, 2) treatment with MK-3415A, MK-6072, or MK-3415, in addition to SOC antibiotic therapy will decrease CDI recurrence as compared to placebo, and 3) MK-3415A, MK-6072, and MK-3415 will be generally well tolerated in participants receiving SOC therapy for CDI as compared to placebo.","primaryOutcome":{"measure":"Percentage of Participants With Clostridium Difficile Infection (CDI) Recurrence","timeFrame":"Up to 12 weeks","effectByArm":[{"arm":"MK-3415 + SOC","deltaMin":25.9,"sd":null},{"arm":"MK-6072 + SOC","deltaMin":17.4,"sd":null},{"arm":"MK-3415A + SOC","deltaMin":15.9,"sd":null},{"arm":"Placebo + SOC","deltaMin":27.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"0.3182"},{"comp":"OG001 vs OG003","p":"0.0003"},{"comp":"OG002 vs OG003","p":"< 0.0001"},{"comp":"OG000 vs OG002","p":"0.0013"},{"comp":"OG001 vs OG002","p":"0.2997"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["36661328","32504314","32376702","32099847","31628838","31411386","30460321","30455246","30227108","30060024","29788418","29538686","28121498","27316794"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":104,"n":235},"commonTop":["Nausea","Diarrhoea","Abdominal pain","Headache","Urinary tract infection"]}}